AI
ACAD icon

Axiom Investors’s Acadia Pharmaceuticals ACAD Stock Holding History

Axiom Investors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-43,206
Closed -$1.54M – 131
2015
Q4 		$1.54M Buy
43,206
+12,182
+39% +$429K 0.05% 111
2015
Q3 		$1.03M Sell
31,024
-22,810
-42% -$949K 0.03% 98
2015
Q2 		$2.25M Buy
53,834
+24,304
+82% +$941K 0.06% 99
2015
Q1 		$962K Buy
+29,530
New +$1.02M 0.03% 132

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Axiom Investors's ACAD Position: Q1 2016 in Review

Axiom Investors sold out of Acadia Pharmaceuticals (ACAD) in Q1 2016, closing a stake of 43,206 shares — an estimated $1.54M sold.

Axiom Investors first reported a position in ACAD in Q1 2015 and held it in 4 quarters. The position peaked at $2.25M in Q2 2015. 213 funds tracked by Wall St. Rank hold ACAD as of Q1 2016.

  • Axiom Investors reported no remaining Acadia Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Axiom Investors sold 43,206 Acadia Pharmaceuticals shares in Q1 2016, an estimated $1.54M.
  • Axiom Investors first reported a position in Acadia Pharmaceuticals in Q1 2015 and held it in 4 quarters.
  • Axiom Investors's Acadia Pharmaceuticals position peaked at $2.25M in Q2 2015.
  • 213 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2016.

Based on Axiom Investors's 13F filing for Q1 2016, filed 12 May 2016.